Pluri (PLUR) AI Stock Analysis

• Market Cap: $32.26M
• Dividend Yield: N/A
• Average Volume (3M): 7.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: 89.92%
• EPS Growth: 21.39%
• Country: US
• Employees: 118
• Sector: Healthcare
• Sector Strength: 76
• Industry: Biotechnology
• EPS (TTM): -3.68
• Shares Outstanding: 6,997,140
• 10 Day Avg. Volume: 12,594
• 30 Day Avg. Volume: 7,484
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 47.58
• Price to Cash Flow (P/CF): -1.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Pluri's overall stock score is low due to significant financial challenges, including negative earnings, high leverage, and poor cash flow. Technical analysis suggests bearish trends, while valuation metrics highlight ongoing financial difficulties. The recent board appointment is a positive development but does not offset the substantial risks. Strategic improvements in financial performance are crucial for future viability.

Pluri Business Overview & Revenue Model

Company Description

null

How the Company Makes Money

null

Pluri Financial Statement Overview

Summary

Pluri faces significant financial challenges across its income statement, balance sheet, and cash flow. The company is struggling with profitability, high leverage, and negative cash flow, all of which pose substantial risks to financial stability. Strategic measures are necessary to improve revenue generation and operational efficiency to ensure long-term viability.

Income Statement

Pluri's income statement reveals persistent challenges, characterized by negative EBIT and EBITDA margins, indicating substantial operational losses. The gross profit margin is exceptionally high in TTM (Trailing-Twelve-Months), but this is offset by significant net losses, resulting in a negative net profit margin. Revenue growth is inconsistent, with occasional increases, but overall revenue remains minimal compared to industry standards.

Balance Sheet

The balance sheet highlights financial instability, with a negative stockholders' equity indicating liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity, suggesting high leverage and financial risk. The company's equity ratio is unfavorably negative, indicative of a weak financial foundation.

Cash Flow

Cash flow statements show negative free cash flow and operating cash flow, reflecting cash outflows exceeding inflows. The free cash flow to net income ratio is unfavorable, and the operating cash flow to net income ratio is also negative, indicating cash flow issues. Despite efforts to raise financing, the cash flow situation remains challenging.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
678.00K	326.00K	287.00K	234.00K	0.00	23.00K
	Gross Profit
11.06M	322.00K	278.00K	-41.36M	-50.62M	-1.55M
	EBIT
-22.47M	-22.16M	-27.25M	-41.59M	-50.62M	-29.48M
	EBITDA
-21.65M	-20.23M	-27.68M	-39.43M	-48.42M	-27.39M
	Net Income Common Stockholders
-15.06M	-20.89M	-28.32M	-41.02M	-49.94M	-29.35M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
21.31M	29.98M	40.17M	55.02M	64.95M	45.78M
	Total Assets
30.86M	39.53M	50.80M	68.06M	93.54M	65.53M
	Total Debt
5.50M	29.61M	29.91M	28.80M	24.58M	1.58M
	Net Debt
5.50M	22.83M	24.55M	19.03M	-6.66M	-6.68M
	Total Liabilities
33.78M	34.11M	35.50M	35.88M	36.39M	9.43M
	Stockholders Equity
-8.03M	96.00K	13.36M	30.04M	57.15M	56.10M
Cash Flow		Free Cash Flow
-12.44M	-18.34M	-23.12M	-36.78M	-31.28M	-26.64M
	Operating Cash Flow
-11.85M	-18.02M	-22.86M	-36.50M	-30.91M	-26.37M
	Investing Cash Flow
3.02M	10.58M	9.70M	11.78M	-7.26M	-30.46M
	Financing Cash Flow
1.34M	8.84M	8.02M	7.50M	61.40M	60.87M

Pluri Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLUR, the sentiment is Positive. The current price of 4.72 is above the 20-day moving average (MA) of 4.57, above the 50-day MA of 4.48, and below the 200-day MA of 5.08, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 55.99 is Neutral, neither overbought nor oversold. The STOCH value of 49.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PLUR.

Pluri Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.86B	0.01	-55.93%	2.48%	24.36%	-2.88%
CRSP	46 Neutral	$3.61B	―	-19.20%	―	-89.95%	-123.71%
BLUE	42 Neutral	$36.53M	―	-270.20%	―	144.50%	-141.91%
FATE	42 Neutral	$107.89M	―	-54.21%	―	-78.55%	-0.92%
EDIT	39 Underperform	$121.15M	―	-98.10%	―	-58.64%	-40.05%
NTLA	39 Underperform	$946.15M	―	-54.00%	―	59.55%	3.09%
PLUR	32 Underperform	$32.26M	―	-1205.58%	―	89.92%	21.39%

Pluri Corporate Events

Pluri Strengthens Leadership Amid Strategic Board Appointment

Pluri Inc. announced the appointment of Mr. Weinstein as a director of the Board, effective immediately upon the closing of a recent offering. Mr. Weinstein has extensive experience in the pharmaceutical, biotechnology, and sustainable technology sectors, and holds positions in several ventures and companies. This appointment is part of a broader strategic move associated with the company’s recent securities offering, which also involves a Securities Purchase Agreement. The move aims to strengthen Pluri’s leadership with Mr. Weinstein’s expertise, potentially impacting the company’s market positioning and operational strategy.